अखिल भारतीय आयुर्विज्ञान संस्थान, रायपुर (छत्तीसगढ़)
**All India Institute of Medical Sciences, Raipur (Chhattisgarh)**
Tatibandh, GE Road,
Raipur-492 099 (CG)
www.aiimsraipur.edu.in

AIIMS/R/HS/30/Drug & Medicine Pharma/2018/RC Date: 01/05/2018

## Corrigendum

**Tender No.** AIIMS/R/HS/30/Drug & Medicine/2018/RC/

**CPPP Tender ID No:-** 2018_IMSRP_32280_1

| S/N. | Page no. /Clause no. as per bid documents | Existing Entry | To be Read as |
|---|---|---|---|
| 1 | Page no. 05, Clause 3 point no.24 | TPN 1000 ml | Total parenteral nutrition solution in three cambered beg for central infusion containing glucose, lipids and amino acids; Volume 1000-1250 ml, total calories at least 900 Kcal osmolality 1000-1250 mOsm/Kg."<br>❖ The inter se ranking of the offer shall be decided on the basis of per ml quoted if offer received strength wise. |
| 2 | Page no. 05 Clause 3, point no.25 | TPN 2000 ml | Total parenteral nutrition solution in three cambered beg for central infusion containing glucose, lipids and amino acids; Volume 1850-2100 ml, total calories at least 1800 Kcal, osmolality 1000-1250 mOsm/Kg. 1850-2100ml"<br>❖ The inter se ranking of the offer shall be decided on the basis of per ml quoted if offer received strength wise. |
| 3 | Page no. 05 Clause 3, point no.15 | Inj. Sodium Nitroprusside vial 50 ml | Inj. Sodium Nitroprusside vial 50 mg/2 ml |
| 4 | Page no. 05 Clause 3, | Inj.Theophylline 50mg+etophylline 170 mg | Inj. Theophylline 50mg+etophylline 170 mg 2 ml vial" |

| | | | |
|---|---|---|---|
| | point no.02 | | |
| 5 | Page No.10 clause 4. (xvii) | WHO –GMP or cGMP as per schedule M (license no. and MFG. unit address highlighted). | WHO–GMP as per schedule M (license no. and MFG. unit address highlighted). |
| 6 | Page No. 10 clause 4 (xviii, d) | A valid WHO-GMP or cGMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act | A valid WHO-GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act |
| 7 | Page No. 11 clause no 4 (xix, e) | WHO-GMP or GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority. | WHO-GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority. |
| 8 | Page No. 12 clause no 5 (5.1, a) | Manufacturer should having valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act. | Manufacturer should having valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (WHO-GMP) of Drugs and Cosmetic Act. |
| 9 | Page No. 12 clause no 5 (5.1.b) | The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on cGMP certificate. | The manufacturer should have received a valid WHO-GMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of WHO-GMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on WHO-GMP certificate. |
| 10 | Page No. 12 clause no 5 (5.2.c) | Manufacturer must have valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act. | Manufacturer must have valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (WHO-GMP) of Drugs and Cosmetic Act. |

| | | | |
|---|---|---|---|
| 11 | Page No. 12 clause no 5 (5.2.d) | The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on GMP certificate. | The manufacturer should have received a valid WHO-GMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of WHO-GMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on WHO- GMP certificate. |
| `12 | As per Tender document | Last date of Submission of tender on 08/05/2018 at 6.00 PM and opening of tender on 10/05/2018 at 11.00 AM | Last date of Submission of tender on 14/05/2018 at 6.00 PM and opening of tender on 16/05/2018 at 11.00 AM |

**Remarks:-**

01. All other terms and condition of tender will remain unchanged.

**Issued by**

**Rishi Gupta**
**Stores Officer (H)**
**AIIMS Raipur (C.G.)**

## Minutes of Pre-bid Meeting

**Sub: Tender No. AIIMS/R/HS/30/DRUG & MEDICINE/2018/RC for the supply DRUG & MEDICINE**

Ref: Pre-bid meeting held on 12.04.2018 at Ayush PMR Building AIIMS Raipur.

The following Bidders' representative attended the pre-bid meeting:

| Sr. No. | Name | Organization/Firm |
|---|---|---|
| 1 | Mr. Akhil sahni | M/s Sai Associates, Raipur |
| 2 | Mr. Kamal Tanwani | M/s Surya Commercial, Raipur |

Following Bidders seek clarifications vide their email :

| Sr. No. | Organization/Firm |
|---|---|
| 1 | M/s Sai Associates Durg |

**Proceeding of the pre-bid meeting is as follows:-**

1. At the outset, a briefing about the scope of services and purpose of the pre-bid meeting were deliberated.
2. Thereafter, prospective bidders were requested to put up their queries related to scope and terms and conditions given in the Bidding Document.
3. The queries from prospective bidders were appropriately responded. The representatives were also requested to send their queries in writing through e-mail within 2 days.
4. The responses to queries sought from prospective bidders in writing and those asked during the meeting have been compiled.
5. The Amendments made pursuance to the Bidding Documents shall be issued separately

**Deliberation:**

| Sr. No. | Page no. /Clause no. as per bid documents | Queries raised by firm | Recommendation / Response |
|---|---|---|---|
| 1 | Page no. 05, Clause 3 point no.24 | **About**:-TPN PERI 1000 ml<br>**Suggestion**:-Latex/PVC free two chambered bag of 1000 ml. each 1000 ml solution should provide: 40-45 gm of Amino Acids, 50-100 gm of carbohydrate and gives 400-500 k cal of total energy and 300-350 K cal of non protein energy along with calcium and other electrolyte. The osmolarity of the solution is 900-1000m Osm/L<br>**Brand:-Nutriflex Peri** | Suitable corrigendum to be followed in this regard |

| | | | |
|---|---|---|---|
| 2 | Page no. 05 Clause 3, point no.25 | **About** :- TPN PERI 2000 ml<br>**Suggestion**:- LatexPVC free three chambered bag of 1000-1500 ml each 1000 ml solution should provided: 50 gm- 60 g of amino acid 125 gm- 150 gm carbohydrate , 40 gm -50 gm of fats (MCT 25 g, Soyabean oil 20 fish 5 g) (MCT: LCT ratio 1:1), Omega 3 : Omega 6 ratio is 1:2.7,1000 k cal -12000 k calof Total energy and 900 k cal- 100 k cal of non protein energy along with calcium , Zinc and other electrolytes for central venous infusion<br>**Brand- Nutriflex omega special N3C 1250 ml IN**<br>**Justification:-**<br>❖ Volume restricted version nutriflex omega comes in volume restricted version offering more calories in less volume, particularly beneficial in volume restricted ICU patient<br>❖ Nutriflex Omega contain Glutamic acid procurer of Glutamine which is crucial in cancer patient having mucosistis<br>❖ ESPEN Guidelines also recommends use of MCT/LCT lipid instead of LCT alone.<br>❖ Nutriflex Omega has omega 3 fatty acid which has a proven impact on length of hospital stay by up to 5 days in patients undergoing major abdominal surgery .Other TPN does not Omega 3 fatty acid of LCT alone which is crucial. | Suitable corrigendum to be followed in this regard |
| 3 | Page no. 05 Clause 3, point no.15 | Inj. Sodium Nitroprusside vial 50 ml | Suitable corrigendum to be followed in this regard |
| 4 | Page no. 05 Clause 3, point no.02 | Inj.Theophylline 50mg+etophylline 170 mg | Suitable corrigendum to be followed in this regard |
| 5 | Page No.10 clause 4. (xvii) | WHO –GMP or cGMP as per schedule M (license no. and MFG. unit address highlighted). | Suitable corrigendum to be followed in this regard |
| 6 | Page No. 10 clause 4 (xviii. d) | A valid WHO-GMP or cGMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act | Suitable corrigendum to be followed in this regard |
| 7 | Page No. 11 clause no 4 (xix. e) | WHO-GMP or GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority. | Suitable corrigendum to be followed in this regard |

| | | | |
|---|---|---|---|
| 8 | Page No. 12 clause no 5 (5.1, a) | Manufacturer should having valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act. | Suitable corrigendum to be followed in this regard |
| 9 | Page No. 12 clause no 5 (5.1,b) | The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on cGMP certificate. | Suitable corrigendum to be followed in this regard |
| 10 | Page No. 12 clause no 5 (5.2,c) | Manufacturer must have valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act. | Suitable corrigendum to be followed in this regard |
| 11 | Page No. 12 clause no 5 (5.2,d) | The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on GMP certificate. | Suitable corrigendum to be followed in this regard. |

**Rishi Gupta**
**Stores Officer (H)**
**AIIMS Raipur (C.G.)**